The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; none of the 55 sources its claims cite is checked for support yet.
Fecal microbiota transplantation: Review and update
Open accessAbstract
Fecal microbiota transplantation (FMT) is a method to directly change the recipient's gut microbiota to normalize the composition and gain a therapeutic benefit. The history of FMT has been traced back to the 4th century and has been highly regarded since 2013, when the United States Food and Drug Administration approved FMT for treating recurrent and refractory Clostridium difficile infection. Since then, the range of FMT applications extended rapidly and broadly not only in gastrointestinal disorders, but also in extra-gastrointestinal diseases. Donor selection with questionnaire, interview, blood tests, and stool examinations should be strictly performed before FMT to reduce and prevent occurrence of any adverse events. Step-by-step cautious fecal and recipient preparation along with adequately choosing delivery methods based on individual clinical situations are key points of the FMT process. Although current evidence deems FMT as a generally safe therapeutic method with few adverse effects, the long-term outcomes of FMT have not been completely elucidated. Therefore, establishing periodicity and length of regular follow-up after FMT to monitor the clinical efficacy and long-term adverse events are other essential issues. In the future, we will look forward to personalized FMT for different patients and conditions according to varied hosts and diseases.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
FMT directly changes the recipient gut microbiota and is established for recurrent/refractory *Clostridium difficile* infection, with expanding investigation in gastrointestinal and extra-gastrointestinal diseases. This review summarizes FMT history, indications, donor/recipient preparation, delivery, safety, regulation, and future directions, noting that long-term outcomes remain incompletely understood.
Key findings
- FMT achieves cure rates up to approximately 90% in recurrent or refractory CDI, compared with 20–30% success for prolonged antimicrobial therapy; it is the only indication approved by the US FDA since 2013.
- Frozen FMT has the same efficacy as fresh FMT for clinical improvement of recurrent or refractory CDI; infusion volumes less than 50 g were associated with up to a four-fold higher risk of failure compared with larger volumes.
- In 80 immunocompromised CDI patients, a multicenter retrospective study found no FMT-related infection events and 78% cure after a single FMT; minor adverse events include abdominal discomfort, diarrhea, constipation, and low-grade fever.
- Beyond CDI, FMT is under investigation for IBD, IBS, metabolic syndrome/obesity, autoimmune and neurologic conditions, multidrug-resistant organism infections, critical illness, and melanoma immunotherapy; response rates in IBD are less impressive than in CDI.
Methods
- Design: narrative review/update; no primary data collection or systematic review methodology is described.
- Data: published literature, clinical trials, meta-analyses, case reports, and expert guidelines; includes tables on indications, donor inclusion/exclusion criteria, donor screening tests, and adverse events.
- Analysis: narrative synthesis of FMT history, indications/contraindications, donor selection, fecal and recipient preparation, delivery methods, monitoring/safety, regulation, and future considerations.
Limitations
- Stated: long-term outcomes of FMT have not been completely elucidated; periodicity and length of follow-up after FMT are not established; long-term immunologic effects have little available information.
- Stated: optimal fecal preparation remains to be determined, no strong evidence supports an optimal FMT delivery method, and appropriate fecal infusion volume is difficult to define.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, risk-of-bias assessment, or quantitative synthesis, so findings depend on heterogeneous published studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 55 cited sources checked · 0 supported · 0 flagged
In the paper
“Several case reports have indicated that there might be some undetermined link between FMT and certain conditions, including peripheral neuropathy, idiopathic thrombocytopenic purpura, Sjo ¨gren's syndrome, and rheumatoid arthritis.17”
§ Fecal microbiota transplantation: Review and update > Patients monitoring and safety issues
What the sources say
- Not checked yetcites [17] Brandt, 2012, Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection, Am J Gastroenterol source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Currently, several randomized clinical trials and meta-analysis demonstrated that frozen FMT has the same efficacy as fresh FMT in clinical improvement of recurrent or refractory CDI.57e59”
§ Fecal microbiota transplantation: Review and update > Fecal preparation
What the sources say
- Not checked yetcites 57e59
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, response rates have not been as impressive as FMT for the indication of CDI.”
§ Fecal microbiota transplantation: Review and update > Indications and contraindications
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Youngster et al. conducted a randomized pilot study comparing upper and lower GI routes of FMT, and the report found a non-significant difference in cure rate between the two different administration methods.67”
§ Fecal microbiota transplantation: Review and update > Delivery methods
What the sources say
- Not checked yetcites [67] Youngster, 2014, Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study, Clin Infect Dis source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Promising case reports and increasing clinical trials demonstrated that FMT may play a useful primary therapeutic role.27e30”
§ Fecal microbiota transplantation: Review and update > Indications and contraindications
What the sources say
- Not checked yetcites 27e30
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Vrieze and colleagues administered FMT in patients with metabolic syndrome, and a significant increase in insulin sensitivity in these subjects was proven after treatment.40”
§ Fecal microbiota transplantation: Review and update > Indications and contraindications
What the sources say
- Not checked yetcites [40] Vrieze, 2012, Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome, Gastroenterology source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Between the different FMT delivery methods, there were no observed differences in the proportion of adverse events.57,58,68”
§ Fecal microbiota transplantation: Review and update > Patients monitoring and safety issues
What the sources say
- Not checked yetcites [57] Tang, 2017, Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: a meta-analysis?, Diagn Microbiol Infect Dis source
- Not checked yetcites [58] Lee, 2016, Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial, JAMA source
- Not checked yetcites [68] Kao, 2017, Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial, JAMA source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Therefore, modified strategies of FMT use, step-up or intensive-dosing multidonor FMT, were performed in IBD patients and indicated beneficial treatment responses.30,31”
§ Fecal microbiota transplantation: Review and update > Indications and contraindications
What the sources say
- Not checked yetcites [30] Paramsothy, 2017, Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial, Lancet source
- Not checked yetcites [31] Cui, 2015, Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis, J Transl Med source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Unrelated FMT volunteer donors may be more beneficial in cases where genetics play a contributing factor in the disease, like IBD. 55”
§ Fecal microbiota transplantation: Review and update > Donor selection
What the sources say
- Not checked yetcites [55] Kelly, 2015, Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook, Gastroenterology source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“US FDA has approved that FMT is composed of a biological product and a drug applied to diagnose, ease, treat, or prevent disease or influence the structure or function of the body.26”
§ Fecal microbiota transplantation: Review and update > Regulation
What the sources say
- Not checked yetcites [26] U.S. Food and Drug Administration. Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 17
- Probably not a substantial claim. 7
In the paper
“A multicenter, retrospective study examined FMT in 80 immunocompromised patients of CDI.There were not only absent infection events related to FMT occurring, but also high cure rates of 78% following a single FMT.11”
§ Fecal microbiota transplantation: Review and update > Patients monitoring and safety issues
What the sources say
- Not checked yetcites [11] Kelly, 2014, Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients, Am J Gastroenterol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Larger volumes of fecal material have shown better FMT outcomes in CDI patients, as demonstrated by a systemic review article, and up to a four-fold higher risk for failure was noted for infusion volumes less than 50 g compared to the larger volume.24”
§ Fecal microbiota transplantation: Review and update > Fecal preparation
What the sources say
- Not checked yetcites [24] Gough, 2011, Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection, Clin Infect Dis source
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The European consensus proposed that the follow-up period after FMT in CDI patients should be at least 8 weeks, and the contents of follow-up must include clinical and analytical data.49”
§ Fecal microbiota transplantation: Review and update > Patients monitoring and safety issues
What the sources say
- Not checked yetcites [49] Cammarota, 2017, European consensus conference on faecal microbiota transplantation in clinical practice, Gut source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The cure rate is surprisingly up to approximately 90% in recurrent or refractory CDI, which is much superior to prolonged anti-microbial therapy with 20e30% success rates.19,24,25”
§ Fecal microbiota transplantation: Review and update > Indications and contraindications
What the sources say
- Not checked yetcites [19] van Nood, 2013, Duodenal infusion of donor feces for recurrent Clostridium difficile, N Engl J Med source
- Not checked yetcites [24] Gough, 2011, Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection, Clin Infect Dis source
- Not checked yetcites [25] Kassam, 2013, Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis, Am J Gastroenterol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, current studies demonstrated FMT can be a cost-saving intervention in managing recurrent and refractory compared to antibiotics use and in moderate-to-severe IBD treatment.32,33”
§ Fecal microbiota transplantation: Review and update > Indications and contraindications
What the sources say
- Not checked yetcites [32] Zhang, 2017, Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease, Oncotarget source
- Not checked yetcites [33] Varier, 2015, Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection, Infect Control Hosp Epidemiol source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Most clinical trials and systemic reviews presented that some minor adverse events, such as abdominal discomfort, diarrhea, constipation, and low-grade fever, were transiently noted after FMT, and uncommon severe side effects were often associated with the possible complications of endoscopy and sedation.17,19,66,70,71”
§ Fecal microbiota transplantation: Review and update > Patients monitoring and safety issues
What the sources say
- Not checked yetcites [17] Brandt, 2012, Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection, Am J Gastroenterol source
- Not checked yetcites [19] van Nood, 2013, Duodenal infusion of donor feces for recurrent Clostridium difficile, N Engl J Med source
- Not checked yetcites [66] Cammarota, 2014, Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review, J Clin Gastroenterol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Several case reports and animal models have also revealed the probable therapeutic effects of FMT in patients with severe multiple sclerosis, 41 autism, 42 multidrug-resistant organisms (MDRO) infections, 43 and multiple organ dysfunction in critical patients.44”
§ Fecal microbiota transplantation: Review and update > Indications and contraindications
What the sources say
- Not checked yetcites [41] Xu, 2015, Fecal microbiota transplantation broadening its application beyond intestinal disorders, World J Gastroenterol source
- Not checked yetcites [42] Aroniadis, 2013, Fecal microbiota transplantation: past, present and future, Curr Opin Gastroenterol source
- Not checked yetcites [43] Crum-Cianflone, 2015, Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization, J Clin Microbiol source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Although the efficacy of retention enema had been once doubted, Orenstein and Dubberke et al. have proven it more efficient and safe than placebo in phase I and phase II recurrent CDI clinical trials.64,65”
§ Fecal microbiota transplantation: Review and update > Delivery methods
What the sources say
- Not checked yetcites [64] Orenstein, 2016, Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study, Clin Infect Dis source
- Not checked yetcites [65] Dubberke, 2018, Results from a randomized placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection, Clin Infect Dis source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Based on current evidence, FMT is viewed as a generally safe therapeutic method with few adverse effects.”
§ Fecal microbiota transplantation: Review and update > Patients monitoring and safety issues
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In the United Kingdom, FMT is also approved for treating CDI, and it is considered safe and effective.14”
§ Fecal microbiota transplantation: Review and update > Regulation
What the sources say
- Not checked yetcites [14] Smith, 2014, Policy: how to regulate faecal transplants, Nature source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Many different groups of diseases are connected to the gut microbiota, including infectious conditions (infectious gastroenteritis, Clostridium difficile infection (CDI)), autoimmune diseases (allergic disease, diabetes, inflammatory bowel disease (IBD)), some general conditions (overweight, functional GI disorders), and behavioral diseases.8”
§ Fecal microbiota transplantation: Review and update > Introduction
What the sources say
- Not checked yetcites [8] Collado, 2015, Gut microbiota: a source of novel tools to reduce the risk of human disease?, Pediatr Res source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The first records of FMT has been traced back to the fourth century China, where human fecal material was called yellow soup and was used in patients of severe diarrhea.15”
§ Fecal microbiota transplantation: Review and update > History of fecal microbiota transplantation
What the sources say
- Not checked yetcites [15] Zhang, 2012, Should we standardize the 1,700-year-old fecal microbiota transplantation?, Am J Gastroenterol source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Borody et al. performed “an exchange of bowel flora” on a 45year old male with refractory ulcerative colitis (UC), showing full and lasting clinical recovery after treatment.20”
§ Fecal microbiota transplantation: Review and update > History of fecal microbiota transplantation
What the sources say
- Not checked yetcites [20] Borody, 1989, Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?, Med J Aust source
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“From a clinical and research perspective, any FMT application beyond treating CDI is deemed “offlabel”; therefore, the benefits and risks of clinical practice must be carefully considered.52”
§ Fecal microbiota transplantation: Review and update > Regulation
What the sources say
- Not checked yetcites [52] Vindigni, 2017, Fecal microbiota transplantation, Gastroenterol Clin N Am source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Some studies suggested loperamide use one hour before FMT in order to ensure that the transplanted feces stay at least 4 h long in the intestines.61e63”
§ Fecal microbiota transplantation: Review and update > Recurrent and refractory Clostridium difficile infection Indications in investigation and potential indications
What the sources say
- Not checked yetcites 61e63
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The human gastrointestinal (GI) tract is colonized by numerous bacterial species, which have the function of aiding digestion, assisting in nutritional provision, facilitating maturation of the colonic epithelium, and protection from pathogens.1e3”
§ Fecal microbiota transplantation: Review and update > Introduction
What the sources say
- Not checked yetcites 1e3
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Human gut microbiome differs by individual and is relatively stable and resilient over time; however, environmental factors, including diet, probiotics, prebiotics, viruses, and drugs, particularly antibiotics, can alter the composition.4e7”
§ Fecal microbiota transplantation: Review and update > Introduction
What the sources say
- Not checked yetcites 4e7
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple studies have demonstrated remarkable effectiveness of FMT in cases of recurrent and refractory CDI, which may be attributed to sustained restoration of the normal microbiota after FMT.22,23”
§ Fecal microbiota transplantation: Review and update > Indications and contraindications
What the sources say
- Not checked yetcites [22] Khoruts, 2010, Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea, J Clin Gastroenterol source
- Not checked yetcites [23] Hamilton, 2012, Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection, Am J Gastroenterol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Health Canada regards FMT as a “New Biologic Drug” and declares that all clinical studies must pass the process of a clinical trial application to ensure it meets quality and safety standards.75”
§ Fecal microbiota transplantation: Review and update > Regulation
What the sources say
- Not checked yetcites [75] Allen-Vercoe, 2012, A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics, Can J Gastroenterol source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, long-term immunologic effects of FMT is another concern, but very little relevant information is available.”
§ Fecal microbiota transplantation: Review and update > Patients monitoring and safety issues
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The optimal preparation of fecal material to manage remains to be determined.”
§ Fecal microbiota transplantation: Review and update > Fecal preparation
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Eiseman and his colleagues successfully treated patients with FMT for pseudomembranous colitis in 1958, the first report in the medical literature.16”
§ Fecal microbiota transplantation: Review and update > History of fecal microbiota transplantation
What the sources say
- Not checked yetcites [16] Eiseman, 1958, Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis, Surgery
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Current therapeutic strategies to correct gut dysbiosis mostly do not present satisfactory clinical effects, except for FMT.
“Currently, a wide variety of medical therapeutic strategies are used to correct gut dysbiosis, but a great majority of them do not present satisfactory clinical effects, except for fecal microbiota transplantation (FMT).”
The paper relies on this without support.
FMT has clinically evident effectiveness.
“clinically evident effectiveness and safety of FMT”
The paper relies on this without support.
FMT has clinically evident safety.
“clinically evident effectiveness and safety of FMT”
The paper relies on this without support.
FMT carries a risk of disease transmission between the donor and recipient.
“risk of disease transmission between the donor and recipient”
The paper relies on this without support.
Patient acceptance is a concern for FMT.
“patients' acceptance”
The paper relies on this without support.
FMT can cause undesirable outcomes.
“undesirable outcomes”
The paper relies on this without support.
FMT has uncertain impacts on the recipient's immune system.
“uncertain impacts on the recipient's immune system”
The paper relies on this without support.
Little is known about the viral or fungal composition in the gut and the function of intestinal bacteria.
“little is known about the viral or fungal composition in the gut and even the function of intestinal bacteria”
The paper relies on this without support.
FMT has the potential to transmit unrecognized infectious agents that cause illness years later (e.g., hepatitis C, HIV).
“Transmission of unrecognized infectious agents that cause illness years later (e.g., hepatitis C, HIV)”
The paper relies on this without support.
FMT has the potential to induce chronic diseases based on alterations in the gut microbiota (e.g., obesity, diabetes, atherosclerosis, IBD, colon cancer, nonalcoholic fatty liver disease, IBS, asthma, autism).
“Induction of chronic diseases based on alterations in the gut microbiota (e.g., obesity, diabetes, atherosclerosis, IBD, colon cancer, nonalcoholic fatty liver disease, IBS, asthma, autism)”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite the therapeutic potential of FMT for the treatment of PD, several limitations still exist and need to be addressed. Standard clinical protocols, delivery methods, periodicity, donor’s selection criteria, patient’s inclusion criteria, long-term benefits and potential risks remain an issue [463,467,481,482,483,484,485].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [485]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
FMT is expanded two different ways
MinorThe abbreviation list defines FMT as "fecal material transplantation," while the abstract defines it as "fecal microbiota transplantation."
“Abbreviations: FMT: fecal material transplantation, HIV: human immunodeficiency virus, IBD: Inflammatory bowel disease.”
“Fecal microbiota transplantation (FMT) is a method to directly change the recipient's gut microbiota to normalize the composition and gain a therapeutic benefit.”
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 576
Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
Marietta, E. V., Mangalam, A. K., Taneja, V., & Murray, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573079 · Cited by 36
The interaction between intestinal microenvironment and stroke
Zhao, L., Xiao, J., Li, S., Guo, Y., Fu, R., Hua, S., Du, Y., & Xu, S. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14275 · Cited by 38
Jamshidi, P. K., Farsi, Y., Nariman, Z., Hatamnejad, M. R., Mohammadzadeh, B., Akbarialiabad, H., Nasiri, M. J., & Sechi, L. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914562 · Cited by 38
Benefits of fecal microbiota transplantation: A comprehensive review
Ademe, M. (2020) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.12780 · Cited by 37
Barqawi, H. J., Adra, S., Ramzi, H. R., Abouaggour, M. A., & Almehairi, S. K. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047869 · Cited by 35
Potential Roles of the Gut Microbiota in Pancreatic Carcinogenesis and Therapeutics
Yang, Q., Zhang, J., & Zhu, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.872019 · Cited by 37
The associations of gut microbiota, endocrine system and bone metabolism
Tu, Y., Kuang, X., Zhang, L., & Xu, X. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1124945 · Cited by 34
The pathogenic role of intestinal flora metabolites in diabetic nephropathy
Tian, E., Wang, F., Zhao, L., Sun, Y., & Yang, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1231621 · Cited by 35
Olteanu, G., Pană, M.-A., Busnatu, Ș., Lupuliasa, D., Neacșu, S. M., Mititelu, M., Musuc, A. M., Ioniță-Mîndrican, C.-B., & Boroghină, S. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105561 · Cited by 36
Alswat, A. S. (2024) · Life · doi:10.3390/life14101279 · Cited by 38
Bacterial extracellular vesicles in osteoarthritis: a new bridge of the gut-joint axis
Niu, L., Chen, W., Yin, Z., Tan, H., Cui, J., & Su, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2489069 · Cited by 35
da Rosa, F. T., Michelotti, T. C., St‐Pierre, B., Trevisi, E., & Osorio, J. S. (2021) · Animals · doi:10.3390/ani11092704 · Cited by 34
Gut microbiota therapy in gastrointestinal diseases
Ullah, H., Arbab, S., Chang, C., Bibi, S., Muhammad, N., Rehman, S. U., Suleman, S., Ullah, I., Hassan, I. U., Tian, Y., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1514636 · Cited by 39
Li, L., Cheng, L., Li, Z., Li, C., Hong, Y., & Gu, Z. (2021) · Food & Function · doi:10.1039/d1fo01913a · Cited by 33
Cruz, N., Abernathy, G. A., Dichosa, A. E. K., & Kumar, A. (2022) · Infection and Immunity · doi:10.1128/iai.00589-21 · Cited by 34
Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy
Nejadghaderi, S. A., Mojarad, E. N., & Aghdaei, H. A. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110476 · Cited by 30
Lu, J., Jin, X., Yang, S., Li, Y., Wang, X., & Wu, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1034537 · Cited by 33
Yu, J., Meng, J., Qin, Z., Yuan, Y., Liang, Y., Wang, Y., & Min, D. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02782-1 · Cited by 30
Self-citationVaginal microbiota: Potential targets for vulvovaginal candidiasis infection
Wang, Y., Liu, Z., & Chen, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27239 · Cited by 36
Self-citationGut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies
Huang, M., Zhang, Y., Chen, Z., Yu, X., Luo, S., Peng, X., & Li, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107726 · Cited by 31
Fecal Microbiota Transplantation: A Microbiome Modulation Technique for Alzheimer’s Disease
Nandwana, V., & Debbarma, S. (2021) · Cureus · doi:10.7759/cureus.16503 · Cited by 30
Nigam, M., Panwar, A. S., & SINGH, R. K. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.961569 · Cited by 33
Baske, M. M., Timmerman, K. C., Garmo, L. G., Freitas, M. N., McCollum, K. A., & Ren, T. Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.088 · Cited by 34
Zhi, W., Li, A., Wang, Q., Yuan, X., Qing, J., Zhang, C., Wang, Y., & Li, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-74171-4 · Cited by 31
Self-citationKim, M., Lee, Y. J., Kim, T., & Won, E. J. (2021) · Microorganisms · doi:10.3390/microorganisms10010034 · Cited by 29
Xin, Y., Liu, C., Zang, D., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343450 · Cited by 33
Wu, X., Zhao, L., Zhāng, Y., Li, K., & Yang, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1166685 · Cited by 29
Thanush, D., Basavaraj, H. C., & Gowrav, M. P. (2023) · Advanced Gut & Microbiome Research · doi:10.1155/2023/6657515 · Cited by 29
Li, H., Jia, M., Qi, Q., & Wang, Q. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01829-23 · Cited by 31
Unlocking the mind-gut connection: Impact of human microbiome on cognition
Castells‐Nobau, A., Mayneris‐Perxachs, J., & Fernández‐Real, J. M. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.019 · Cited by 31
Żebrowska-Różańska, P., Łaczmańska, I., & Łaczmański, Ł. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.630052 · Cited by 32
Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy
Shelkey, E., Oommen, D., Stirling, E. R., Soto‐Pantoja, D. R., Cook, K. L., Lu, Y., Votanopoulos, K. I., & Söker, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13930-7 · Cited by 29
Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data
Krišto, M., Lugović‐Mihić, L., Muñoz, M., Rupnik, M., Mahnič, A., Ozretić, P., Jaganjac, M., Ćesić, D., & Kuna, M. (2023) · Life · doi:10.3390/life13010152 · Cited by 28
Shah, Y. R., Ali, H., Tiwari, A., Guevara-Lazo, D., Nombera-Aznaran, N., Pinnam, B. S. M., Gangwani, M. K., Gopakumar, H., Sohail, A. H., Kanumilli, S., et al. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i1.17 · Cited by 30
Hwang, S. W., Kim, M. K., & Kweon, M. (2023) · Intestinal Research · doi:10.5217/ir.2023.00019 · Cited by 28
Intestinal Microbiota in Sepsis
Sun, T., Wang, L., & Zhang, H. (2022) · Intensive Care Research · doi:10.1007/s44231-022-00001-8 · Cited by 26
Chen, M.-M., Liu, M., Li, C., Peng, S., Li, Y., Xu, X., Sun, M., & Sun, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.913217 · Cited by 29
Tan, X.-Y., Xie, Y.-J., Liu, X., Li, X., & Jia, B. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8266793 · Cited by 27
The Effect of Gut Microbiota on the Progression of Intervertebral Disc Degeneration
Yao, B., Cai, Y., Wang, W., Deng, J., Zhao, L., Han, Z., & Wan, L. (2023) · Orthopaedic Surgery · doi:10.1111/os.13626 · Cited by 28
Microbiome Responses to Fecal Microbiota Transplantation in Cats with Chronic Digestive Issues
Rojas, C. A., Entrolezo, Z., Jarett, J. K., Jospin, G., Kingsbury, D. D., Martin, A., Eisen, J. A., & Ganz, H. H. (2023) · Veterinary Sciences · doi:10.3390/vetsci10090561 · Cited by 31
Dingenen, L. V., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar‐Singh, S., Malhotra‐Kumar, S., & Houdt, R. V. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1298264 · Cited by 29
Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases
Anwer, E. K. E., Ajagbe, M., Sherif, M. A., Musaibah, A. S., Mahmoud, S., ElBanbi, A., & Abdelnaser, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010100 · Cited by 31
Exploring the Gut Microbiota–Retina Axis: Implications for Health and Disease
Schiavone, N., Isoldi, G., Calcagno, S., Rovida, E., Antiga, E., Almeida, C. V. D., & Lulli, M. (2025) · Microorganisms · doi:10.3390/microorganisms13051101 · Cited by 27
Regulatory framework and challenges for live biotherapeutic products in Taiwan
Pan, S., Hsu, J.-C., Hung, K.-T., & Ho, C.-J. (2025) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3540 · Cited by 26
Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma
Yu, Q., Wu, L., Ji, J., Feng, J., Dai, W., Li, J., Wu, J., & Guo, C. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s277870 · Cited by 27
Amedei, A., Capasso, C., Nannini, G., & Supuran, C. T. (2021) · Mediators of Inflammation · doi:10.1155/2021/6926082 · Cited by 26
Diet-microbiome-gut-brain nexus in acute and chronic brain injury
Krakovski, M., Arora, N., Jain, S., Glover, J., Dombrowski, K. E., Hernandez, B., Yadav, H., & Sarma, A. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1002266 · Cited by 27
Jensen, C., Antonsen, M. F., & Lied, G. A. (2022) · Microorganisms · doi:10.3390/microorganisms10101904 · Cited by 27
The role of microbiota in the development and treatment of gastric cancer
Wang, Y., Han, W., Wang, N., Han, M., Ban, M., Dai, J., Dong, Y., Sun, T., & Xu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1224669 · Cited by 27
Self-citationDevelopmental programming of adult haematopoiesis system
Balistreri, C. R., Garagnani, P., Madonna, R., Vaiserman, A. M., & Melino, G. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100918 · Cited by 29
Chan, D. G., Ventura, K., Villeneuve, A., Du Bois, P., & Holahan, M. R. (2022) · Journal of Parkinson's Disease · doi:10.3233/jpd-223461 · Cited by 24
Vasiliu, O. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2124071 · Cited by 30
The role of the gut microbiome and its metabolites in cerebrovascular diseases
Xu, H., Xu, Z., Long, S., Li, Z., Jiang, J., Zhou, Q., Huang, X., Wu, X., Wei, W., & Li, X. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1097148 · Cited by 26
Human gut microbiome: Therapeutic opportunities for metabolic syndrome—Hype or hope?
Horvath, A., Žukauskaitė, K., Hazia, O., Balázs, I., & Stadlbauer, V. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.436 · Cited by 30
Fecal Microbiota Transplantation in Patients with Alcohol-Associated Cirrhosis: A Clinical Trial
Ichim, C., Boicean, A., Todor, S. B., Anderco, P., & Bîrluțiu, V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14175981 · Cited by 24
Tutorial on Diarrhea and Enteral Nutrition: A Comprehensive Step‐By‐Step Approach
Pitta, M. R., Campos, F. M., Monteiro, A. G., Cunha, A. G. F., Porto, J. D., & Gomes, R. R. (2019) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1674 · Cited by 24
The relationship between atrial fibrillation and NLRP3 inflammasome: a gut microbiota perspective
Xing, Y., Yan, L., Li, X., Xu, Z., Wu, X., Gao, H., Chen, Y., Ma, X., Liu, J., & Zhang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1273524 · Cited by 29
Abenavoli, L., Gambardella, M. L., Scarlata, G. G. M., Lenci, I., Baiocchi, L., & Luzza, F. (2024) · Medicina · doi:10.3390/medicina60040563 · Cited by 22
The gut microbiota-brain connection: insights into major depressive disorder and bipolar disorder
Zhao, J. W., Liu, J., Feng, J., Liu, X., & Hu, Q. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1421490 · Cited by 25
The frontier of health: Exploring therapeutic potentials of the microbiome
Abavisani, M., Foroushan, S. K., Kesharwani, P., & Sahebkar, A. (2025) · PharmaNutrition · doi:10.1016/j.phanu.2025.100435 · Cited by 23
Fecal microbiota transplantation in childhood: past, present, and future
Gu, X., Chen, Z.-H., & Zhang, S. (2022) · World Journal of Pediatrics · doi:10.1007/s12519-022-00655-w · Cited by 25
Zhou, M., Yu, J., Li, X., Ruan, Z., & Yu, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18258 · Cited by 25
Intestinal flora and bile acid interactions impact the progression of diabetic kidney disease
Xu, J., Wang, N., Yang, L., Zhong, J., & Chen, M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1441415 · Cited by 23
Spinal cord injury: pathophysiology, possible treatments and the role of the gut microbiota
Pagán-Rivera, L. H., Ocasio-Rivera, S. E., Godoy‐Vitorino, F., & Miranda, J. D. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1490855 · Cited by 23
Gut Microbiota: A New Challenge in Mood Disorder Research
Marano, G., Rossi, S., Sfratta, G., Traversi, G., Lisci, F. M., Anesini, M. B., Pola, R., Gasbarrini, A., Gaetani, E., & Mazza, M. (2025) · Life · doi:10.3390/life15040593 · Cited by 29
Fecal microbiota transplantation: Current evidence and future directions
Cymbal, M., Chatterjee, A., & Baggott, B. B. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24107 · Cited by 23
Deciphering the role of gut metabolites in non-alcoholic fatty liver disease
Ralli, T., Saifi, Z., Tyagi, N., Vidyadhari, A., Aeri, V., & Kohli, K. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2142091 · Cited by 22
Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome?
Kapoor, B., Gulati, M., Gupta, R., & Singla, R. K. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103313 · Cited by 25
Chen, Z., Ding, C., Gu, Y., He, Y., Chen, B. Y., Zheng, S., & Li, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120515 · Cited by 22
Impact of the Microbiota on Viral Infections
Campbell, D. E., Li, Y., Ingle, H., & Baldridge, M. T. (2023) · Annual Review of Virology · doi:10.1146/annurev-virology-111821-115754 · Cited by 22
Cai, X. T., Li, Z., Yao, Y., Zheng, Y., Zhang, M., & Ye, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115951 · Cited by 22
Bahitham, W., Alghamdi, S., Omer, I., Alsudais, A. S., Hakeem, I., Alghamdi, A., Abualnaja, R., Sanai, F. M., Rosado, A. S., & Sergi, C. M. (2024) · Biomedicines · doi:10.3390/biomedicines12030550 · Cited by 22
Shao, W., Pan, B., Li, Z., Peng, R., Yang, W., Xie, Y., Han, D., Fang, X., Li, J., Zhu, Y., et al. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.135096 · Cited by 22
Wang, J., Yang, H.-R., Wang, D.-J., & Wang, X.-X. (2020) · Oncology Letters · doi:10.3892/ol.2020.12205 · Cited by 22
Self-citationTakáčová, M., Bomba, A., Tóthová, C., Micháľová, A., & Turňa, H. (2022) · Life · doi:10.3390/life12050723 · Cited by 24
Fülöpová, N., Pavloková, S., Debono, I., Vetchý, D., & Franc, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081577 · Cited by 21
Bacteria-driven bio-therapy: From fundamental studies to clinical trials
Yu, Y., Lin, S., Chen, Z., Qin, B. Y., He, Z., Cheng, M., Sun, M., & Sun, J. Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101731 · Cited by 23
Biomolecular Actions by Intestinal Endotoxemia in Metabolic Syndrome
Charitos, I. A., Aliani, M., Tondo, P., Venneri, M. G., Castellana, G., Scioscia, G., Castellaneta, F., Lacedonia, D., & Carone, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052841 · Cited by 26
Bocchio, F., Mancabelli, L., Milani, C., Lugli, G. A., Tarracchini, C., Longhi, G., Conto, F. D., Turroni, F., & Ventura, M. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2024.52 · Cited by 28
Strategies to reduce uric acid through gut microbiota intervention
Cui, Y., An, P., Li, F., Duan, F., Mei, Z., Qiao, Y., Wang, G., Zhang, H., & Luo, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1654152 · Cited by 21
Li, F., Jiang, L., Pan, S., Jiang, S., Fan, Y., Jiang, C., Gao, C., & Leng, Y. (2022) · mSystems · doi:10.1128/msystems.01204-21 · Cited by 21
The role of the gut microbiota and fecal microbiota transplantation in neuroimmune diseases
Wu, N., Li, X., Ma, H., Zhang, X., Liu, B., Yuan, W., Zheng, Q., & Fan, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1108738 · Cited by 22
The Role of the Microbiome in the Pathogenesis and Treatment of Asthma
Logoń, K., Świrkosz, G., Nowak, M., Wrześniewska, M., Szczygieł, A., & Gomułka, K. (2023) · Biomedicines · doi:10.3390/biomedicines11061618 · Cited by 22
Guha, L., Agnihotri, T. G., Jain, A., & Kumar, H. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122193 · Cited by 20
Ali, H. Q., Khurana, S., Ma, W., Peng, Y., Jiang, Z., DuPont, H. L., Zhang, H. C., Thomas, A. S., Okhuysen, P. C., & Wang, Y. (2021) · Journal of Cancer · doi:10.7150/jca.59251 · Cited by 19
Self-citationAntibiotic-Induced Dysbiosis of the Gut Microbiota Impairs Gene Expression in Gut-Liver Axis of Mice
Liu, P., Zhang, Y., Zhang, Z., Huang, X., Su, X., Yang, S., & Xie, Y. (2023) · Genes · doi:10.3390/genes14071423 · Cited by 19
Zeng, H., Zhou, K., Zhuang, Y., Li, A., Luo, B., & Zhang, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1273104 · Cited by 19
Metabolites: a converging node of host and microbe to explain meta-organism
Chakraborty, N. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1337368 · Cited by 21
Zong, H., Fei, Y., & Liu, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115179 · Cited by 21
Maor, M., Barazany, H. L., & Kolodkin‐Gal, I. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2517377 · Cited by 18
YouTube as a source of information on systemic sclerosis
Unal‐Ulutatar, C., & Ulutatar, F. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14363 · Cited by 18
Xie, Y., Li, X., Xu, D., He, D., Wang, J., Bi, J., Liu, J., & Fu, S. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c02867 · Cited by 18
Self-citationSingh, A. K., Kishore, P. S., & Khan, S. (2024) · Cureus · doi:10.7759/cureus.70877 · Cited by 21
The protective role of commensal gut microbes and their metabolites against bacterial pathogens
Cheng, L., Correia, M. S. P., Higdon, S. M., García, F. R., Tsiara, I., Joffré, E., Sjöling, Å., Boulund, F., Norin, E. L., Engstrand, L. G., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2356275 · Cited by 17
Gut microbiota, metabolites, and pulmonary hypertension: Mutual regulation and potential therapies
Yang, J., Liu, J., Gu, H., Song, W., Zhang, H., Yang, P. B., & Yang, P. B. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128245 · Cited by 19
Gut Microbiota Interventions for the Management of Obesity: A Literature Review
Gill, V. J. S., Soni, S., Shringarpure, M., ., A., Bhardwaj, S., Yadav, N. K., Patel, A., & Patel, A. (2022) · Cureus · doi:10.7759/cureus.29317 · Cited by 19
Varga, A., Makszin, L., Bufa, A., Sipos, D., Kása, P., Pál, S., Rosenstiel, P. C., Sommer, F., Kocsis, B., & Péterfi, Z. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1041384 · Cited by 17
Wang, J., Zhang, X., Yang, X., Yu, H., Bu, M.-M., Fu, J., Zhang, Z., Xu, H., Hu, J., Lu, J., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1191936 · Cited by 18
Self-citationFecal Capsule as a Therapeutic Strategy in IgA Nephropathy: A Brief Report
Zhi, W., Song, W., Saed, Y. A., Wang, Y., & Li, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.914250 · Cited by 17
Self-citationLiu, Q., Hua, Y., He, R., Xiang, L., Li, Y., Zhang, Y., Chen, R., Li, Q., Jiang, X., Wang, C., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102130 · Cited by 16
Metadata
- Authors
- Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C.
- Affiliations
- Kaohsiung Medical University (TW)
- E-Da Hospital (TW)
- Kaohsiung Municipal Hsiao-Kang Hospital (TW)
- Kaohsiung Veterans General Hospital (TW)
- Corresponding author
- Wu, Deng-Chyang
- ORCID
- Venue
- Journal of the Formosan Medical Association
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 118
- Pages
- S23-S31
- ISSN
- 0929-6646 (ISSN-L)
- OpenAlex
- W2889311756
- Cited by
- 576
- References
- 75
- Citations by year
- 2026: 57 · 2025: 121 · 2024: 108 · 2023: 112 · 2022: 85 · 2021: 50 · 2020: 32 · 2019: 11
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the Formosan Medical Association (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Kaohsiung Municipal Ta-Tung Hospital, Taiwan (KMTTH-106-028)
- Kaohsiung Medical University Hospital, Taiwan (KMUH106-6R02)
- Ministry of Health and Welfare, Taiwan (MOHW106-TDU-B-212-113006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, gut microbiota, Clostridium difficile infection, donor selection, long-term follow-up, extraintestinal diseases, gastrointestinal diseases
- MeSH terms
- Fecal Microbiota Transplantation, Clostridium Infections, Gastrointestinal Diseases, Humans, Recurrence, Randomized Controlled Trials as Topic, Clostridioides difficile, Treatment Outcome, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
